Halyard Health (NYSE:HYH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The brokerage presently has a $53.00 price objective on the medical instruments supplier’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 11.18% from the stock’s current price.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
A number of other research analysts have also issued reports on HYH. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Stifel Nicolaus restated a “buy” rating and issued a $45.00 target price on shares of Halyard Health in a report on Thursday, September 21st. KeyCorp restated a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th. TheStreet lowered shares of Halyard Health from a “b-” rating to a “c+” rating in a report on Monday, October 30th. Finally, ValuEngine upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $46.25.
Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.13. The company had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.48 EPS. analysts predict that Halyard Health will post 2.08 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in HYH. Teachers Advisors LLC lifted its holdings in shares of Halyard Health by 1.5% during the 1st quarter. Teachers Advisors LLC now owns 83,319 shares of the medical instruments supplier’s stock worth $3,174,000 after acquiring an additional 1,249 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Halyard Health during the 1st quarter worth about $727,000. Capstone Asset Management Co. lifted its holdings in shares of Halyard Health by 6.2% during the 2nd quarter. Capstone Asset Management Co. now owns 5,663 shares of the medical instruments supplier’s stock worth $222,000 after acquiring an additional 330 shares during the period. LS Investment Advisors LLC lifted its holdings in shares of Halyard Health by 16.1% during the 2nd quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 556 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Halyard Health by 6.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 15,517 shares of the medical instruments supplier’s stock worth $572,000 after acquiring an additional 1,000 shares during the period. Institutional investors and hedge funds own 90.31% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Halyard Health (HYH) Stock Rating Upgraded by Zacks Investment Research” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/06/halyard-health-hyh-stock-rating-upgraded-by-zacks-investment-research.html.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
What are top analysts saying about Halyard Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halyard Health Inc. and related companies.